BTBD10: Key Regulator of T-Cell Receptor and Cancer Development

Target Name: BTBD10

NCBI ID: G84280

BTBD10

BTBD10: Key Regulator of T-Cell Receptor and Cancer Development

BTBD10, also known as BTB/POZ domain-containing protein 10, is a protein that is expressed in a variety of tissues and cells throughout the body. It is a member of the BTB/POZ protein family, which is characterized by the presence of a BTB domain and a POZ domain. The BTB domain is a conserved region that is found in a variety of proteins that is involved in protein-protein interactions, while the POZ domain is a unique region that is found in only a small number of proteins.

The BTBD10 protein is involved in a variety of cellular processes, including cell signaling, cell adhesion, and protein degradation. It is a key regulator of the T-cell receptor (TCR), which is a critical component of the immune system that allows T-cells to recognize and respond to foreign substances in the body. BTBD10 is also involved in the regulation of cell cycle progression, and it has been shown to play a role in the development and progression of cancer.

In addition to its role in cell signaling and cell adhesion, BTBD10 is also involved in the regulation of protein degradation. It is a protein that is involved in the degradation of the protein known as p16INK4a, which is a negative regulator of the T-cell receptor. The degradation of p16INK4a by BTBD10 is important for maintaining the activity and stability of the T-cell receptor.

BTBD10 is also involved in the regulation of cell cycle progression. It is a protein that is involved in the G1/S transition, which is a critical stage in the cell cycle where the cell prepares for cell division. During the G1/S transition, BTBD10 helps to ensure that the cell maintains an accurate copy of its genetic material and that it is prepared for cell division.

In addition to its role in cell signaling and cell adhesion, BTBD10 is also involved in the regulation of protein degradation. It is a protein that is involved in the degradation of the protein known as p16INK4a, which is a negative regulator of the T-cell receptor. The degradation of p16INK4a by BTBD10 is important for maintaining the activity and stability of the T-cell receptor.

BTBD10 is also involved in the regulation of cell cycle progression. It is a protein that is involved in the G1/S transition, which is a critical stage in the cell cycle where the cell prepares for cell division. During the G1/S transition, BTBD10 helps to ensure that the cell maintains an accurate copy of its genetic material and that it is prepared for cell division.

BTBD10 has also been shown to play a role in the development and progression of cancer. It is a protein that is involved in the regulation of cell adhesion and cell signaling, which are critical processes that are important for the growth and survival of cancer cells. BTBD10 has been shown to be involved in the regulation of cell adhesion, and it has been shown to play a role in the development and progression of cancer.

In conclusion, BTBD10 is a protein that is involved in a variety of cellular processes, including cell signaling, cell adhesion, and protein degradation. It is a key regulator of the T-cell receptor and is involved in the regulation of cell cycle progression, and it has been shown to play a role in the development and progression of cancer. As a result, BTBD10 may be a valuable drug target or biomarker for the development of new cancer therapies.

Protein Name: BTB Domain Containing 10

Functions: Plays a major role as an activator of AKT family members by inhibiting PPP2CA-mediated dephosphorylation, thereby keeping AKTs activated. Plays a role in preventing motor neuronal death and accelerating the growth of pancreatic beta cells

The "BTBD10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BTBD10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets